Anthem Biosciences Limited (NSE:ANTHEM)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Contract Research Development & Manufacturing Services (CRDMO)	17.73B	15.06B	8.98B	8.08B	9.47B
Contract Research Development & Manufacturing Services (CRDMO) Growth	17.71%	67.79%	11.08%	-14.69%	-4.94%
Speciality Ingredients	3.52B	3.38B	3.36B	2.49B	2.84B
Speciality Ingredients Growth	3.88%	0.68%	35.11%	-12.40%	165.96%
R & D Services	-	-	1.86B	-	-
Total	21.24B	18.45B	14.19B	10.57B	12.31B
Total Growth	15.17%	29.96%	34.29%	-14.16%	11.60%

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
North America (USA)	5.80B	4.99B	4.29B	5.00B	5.18B
North America (USA) Growth	16.11%	16.46%	-14.31%	-3.38%	-8.19%
Europe	11.45B	9.97B	6.13B	3.06B	4.60B
Europe Growth	14.88%	62.49%	100.35%	-33.38%	60.58%
India	3.16B	3.06B	3.10B	2.13B	2.32B
India Growth	3.36%	-1.32%	45.34%	-8.08%	45.05%
Rest of Asia & Others	837.75M	430.20M	676.71M	374.95M	222.01M
Rest of Asia & Others Growth	94.74%	-36.43%	80.48%	68.89%	-
Total	21.24B	18.45B	14.19B	10.57B	12.31B
Total Growth	15.17%	29.96%	34.29%	-14.16%	11.60%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 9, 2026

Data Sources Report a data error